SCHEMBL3474802

SCHEMBL3474802

C#CCCS(C)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13372421 0.83
SCHEMBL3477097 0.81 ALDH1A1 (0.43)
SCHEMBL6725195 0.79
SCHEMBL12854157 0.74
SCHEMBL4650378 0.73
SCHEMBL10712850 0.71
SCHEMBL5708005 0.71
Dapansutrile SCHEMBL9934796 0.71
SCHEMBL14895482 0.71
SCHEMBL14351421 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319698-B2 Proteasome activity enhancing compounds Kineta, Inc. (US) 2025-06-03 US disclosed
CN-112585132-B Proteasome activity enhancing compounds 优曼尼蒂公司 2025-02-28 CN disclosed
US-20230183256-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS YUMANITY THERAPEUTICS, INC. 2023-06-15 US disclosed
WO-2023088234-A1 LITHIUM ION BATTERY ELECTROLYTE SOLUTION AND LITHIUM ION BATTERY 浙江省化工研究院有限公司 2023-05-25 WO disclosed
US-11560385-B2 Proteasome activity enhancing compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2023-01-24 US disclosed
EP-3814338-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS Proteostasis Therapeutics, Inc. (US) 2021-05-05 EP disclosed
US-20210115057-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. 2021-04-22 US disclosed
CN-112585132-A Proteasome activity enhancing compounds 蛋白质平衡治疗股份有限公司 2021-03-30 CN disclosed
US-9920042-B2 Compounds for use in the treatment of mycobacterial infections UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) 2018-03-20 US disclosed
US-20160324880-A1 4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS PARATEK PHARMACEUTICALS, INC. 2016-11-10 US disclosed
US-20030105133-A1 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists BIGGE CHRISTOPHER F (US) 2003-06-05 US disclosed
EP-0869791-B1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 2003-05-07 EP disclosed
US-20020198233-A1 Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethly)-1-piperidinyl]-butyl]-alpha,alpha-dimethylbenzeneacetic acid DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. (IT) 2002-12-26 US disclosed
EP-1260505-A1 A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid Dinamite Dipharma S.p.A. (IT) 2002-11-27 EP disclosed
US-6448270-B1 BICYCLIC HETEROARYL ACETYLENES; NEUROPROTECTIVE AGENTS; STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTIC INDUCED HEARING LOSS, MIGRAINES, CHRONIC PAIN, GLAUCOMA WARNER-LAMBERT COMPANY 2002-09-10 US disclosed
US-6130234-A 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists WARNER-LAMBERT COMPANY (US) 2000-10-10 US disclosed
EP-0869791-A4 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 1999-04-28 EP disclosed
EP-0869791-A1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1998-10-14 EP disclosed
WO-1997023202-A1 SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-07-03 WO disclosed
WO-1997023214-A1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 WO disclosed